FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2006116919> ?p ?o ?g. }

• W2006116919 endingPage "1424" @default.
• W2006116919 startingPage "1416" @default.
• W2006116919 abstract "The recognition of a number of leukemia-specific cytogenetic abnormalities and their role as independent prognostic factors have provided considerable insights into leukemia pathogenesis and have paved the way to adopt risk-adapted treatment. However, approximately 50% of newly diagnosed acute myeloid leukemia (AML) have a normal karyotype. There has therefore been much interest in identifying molecular markers that could help to improve the prognostic stratification of patients with normal-karyotype AML.Consecutive untreated AML patients (n = 67) from a single institution all with normal karyotype were analyzed for the presence of mutations in the myeloid transcription factor gene CEBPA (for CCAAT/enhancer binding protein-alpha), for internal tandem duplications (ITD) of the tyrosine kinase receptor gene FLT3 (for fms-like tyrosine kinase 3), and for expression of the BAALC gene (for brain and acute leukemia, cytoplasmic).17.9% of normal-karyotype AML had mutations in the CEBPA gene, and 28.4% had FLT3-ITD; 65.7% (44 of 67) had high BAALC expression and 34.3% (23 of 67) had low BAALC expression. Patients with CEBPA mutations had a very favorable course of their disease. Median disease-free survival (DFS) and overall survival (OS) were 33.5 and 45.5 months, respectively, compared with 10 (e.g., 12 months in patients without CEBPA mutations; P = 0.0017; P = 0.0007). AML patients with FLT3-ITD had significantly shorter median DFS (P = 0.0328) and OS (P = 0.0148) than patients without FLT3-ITD. High BAALC expression predicted for a shorter DFS (P = 0.0152) and OS (P = 0.0210) compared with AML with low BAALC expression; 53.7% of normal-karyotype AML had neither FLT3-ITD nor CEBPA mutations. We found that high BAALC expression in normal-karyotype AML with neither FLT3-ITD nor CEBPA mutations (18 of 67) indicates adverse prognosis for both DFS and OS (P = 0.0001; e.g., P = 0.0001) compared with the group with low BAALC expression and absent FLT3-ITD and CEBPA mutations (18 of 67). Thus, BAALC expression represents a novel prognostic marker particularly for normal-karyotype AML patients with neither FLT3-ITD nor CEBPA mutations.Assessment of CEBPA mutations, FLT3-ITD, and BAALC expression permits to split normal-karyotype AML into clinically distinct subgroups." @default.
• W2006116919 created "2016-06-24" @default.
• W2006116919 creator A5000513493 @default.
• W2006116919 creator A5014379543 @default.
• W2006116919 creator A5041833929 @default.
• W2006116919 creator A5041892684 @default.
• W2006116919 creator A5046713117 @default.
• W2006116919 creator A5067941053 @default.
• W2006116919 creator A5072978771 @default.
• W2006116919 creator A5090969657 @default.
• W2006116919 date "2005-02-15" @default.
• W2006116919 modified "2023-10-03" @default.
• W2006116919 title "Risk Assessment in Patients with Acute Myeloid Leukemia and a Normal Karyotype" @default.
• W2006116919 cites W1492609361 @default.
• W2006116919 cites W1983663468 @default.
• W2006116919 cites W1987598864 @default.
• W2006116919 cites W2004477791 @default.
• W2006116919 cites W2005486003 @default.
• W2006116919 cites W2041027929 @default.
• W2006116919 cites W2050249118 @default.
• W2006116919 cites W2051743028 @default.
• W2006116919 cites W2056777862 @default.
• W2006116919 cites W2078481381 @default.
• W2006116919 cites W2100088478 @default.
• W2006116919 cites W2106473110 @default.
• W2006116919 cites W2114538465 @default.
• W2006116919 cites W2119626196 @default.
• W2006116919 cites W2127621383 @default.
• W2006116919 cites W2129615499 @default.
• W2006116919 cites W2129951747 @default.
• W2006116919 cites W2132912591 @default.
• W2006116919 cites W2143297156 @default.
• W2006116919 cites W2150470057 @default.
• W2006116919 cites W2159170728 @default.
• W2006116919 cites W2162309072 @default.
• W2006116919 cites W2172276903 @default.
• W2006116919 cites W4246142716 @default.
• W2006116919 doi "https://doi.org/10.1158/1078-0432.ccr-04-1552" @default.
• W2006116919 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15746041" @default.
• W2006116919 hasPublicationYear "2005" @default.
• W2006116919 type Work @default.
• W2006116919 sameAs 2006116919 @default.
• W2006116919 citedByCount "226" @default.
• W2006116919 countsByYear W20061169192012 @default.
• W2006116919 countsByYear W20061169192013 @default.
• W2006116919 countsByYear W20061169192014 @default.
• W2006116919 countsByYear W20061169192015 @default.
• W2006116919 countsByYear W20061169192016 @default.
• W2006116919 countsByYear W20061169192017 @default.
• W2006116919 countsByYear W20061169192018 @default.
• W2006116919 countsByYear W20061169192019 @default.
• W2006116919 countsByYear W20061169192020 @default.
• W2006116919 countsByYear W20061169192021 @default.
• W2006116919 countsByYear W20061169192022 @default.
• W2006116919 countsByYear W20061169192023 @default.
• W2006116919 crossrefType "journal-article" @default.
• W2006116919 hasAuthorship W2006116919A5000513493 @default.
• W2006116919 hasAuthorship W2006116919A5014379543 @default.
• W2006116919 hasAuthorship W2006116919A5041833929 @default.
• W2006116919 hasAuthorship W2006116919A5041892684 @default.
• W2006116919 hasAuthorship W2006116919A5046713117 @default.
• W2006116919 hasAuthorship W2006116919A5067941053 @default.
• W2006116919 hasAuthorship W2006116919A5072978771 @default.
• W2006116919 hasAuthorship W2006116919A5090969657 @default.
• W2006116919 hasConcept C104317684 @default.
• W2006116919 hasConcept C126322002 @default.
• W2006116919 hasConcept C143998085 @default.
• W2006116919 hasConcept C174475383 @default.
• W2006116919 hasConcept C2483381 @default.
• W2006116919 hasConcept C2778461978 @default.
• W2006116919 hasConcept C2778729363 @default.
• W2006116919 hasConcept C2779282312 @default.
• W2006116919 hasConcept C2910954276 @default.
• W2006116919 hasConcept C30481170 @default.
• W2006116919 hasConcept C45091340 @default.
• W2006116919 hasConcept C501734568 @default.
• W2006116919 hasConcept C502942594 @default.
• W2006116919 hasConcept C53226629 @default.
• W2006116919 hasConcept C54355233 @default.
• W2006116919 hasConcept C71924100 @default.
• W2006116919 hasConcept C86803240 @default.
• W2006116919 hasConceptScore W2006116919C104317684 @default.
• W2006116919 hasConceptScore W2006116919C126322002 @default.
• W2006116919 hasConceptScore W2006116919C143998085 @default.
• W2006116919 hasConceptScore W2006116919C174475383 @default.
• W2006116919 hasConceptScore W2006116919C2483381 @default.
• W2006116919 hasConceptScore W2006116919C2778461978 @default.
• W2006116919 hasConceptScore W2006116919C2778729363 @default.
• W2006116919 hasConceptScore W2006116919C2779282312 @default.
• W2006116919 hasConceptScore W2006116919C2910954276 @default.
• W2006116919 hasConceptScore W2006116919C30481170 @default.
• W2006116919 hasConceptScore W2006116919C45091340 @default.
• W2006116919 hasConceptScore W2006116919C501734568 @default.
• W2006116919 hasConceptScore W2006116919C502942594 @default.
• W2006116919 hasConceptScore W2006116919C53226629 @default.
• W2006116919 hasConceptScore W2006116919C54355233 @default.
• W2006116919 hasConceptScore W2006116919C71924100 @default.
• W2006116919 hasConceptScore W2006116919C86803240 @default.

• next